<?xml version='1.0' encoding='utf-8'?>
<document id="31678378"><sentence text="Transdermal enhancement strategy of ketoprofen and teriflunomide: The effect of enhanced drug-drug intermolecular interaction by permeation enhancer on drug release of compound transdermal patch."><entity charOffset="36-46" id="DDI-PubMed.31678378.s1.e0" text="ketoprofen" /><entity charOffset="51-64" id="DDI-PubMed.31678378.s1.e1" text="teriflunomide" /><pair ddi="false" e1="DDI-PubMed.31678378.s1.e0" e2="DDI-PubMed.31678378.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s1.e0" e2="DDI-PubMed.31678378.s1.e1" /></sentence><sentence text="The aim of the present work was to develop compound transdermal patch containing teriflunomide (TEF) and ketoprofen (KTP) using permeation enhancement strategy; reveal the molecular mechanism by which Azone (AZ) promoted transdermal absorption of compound patch through the enhancement of drug-drug intermolecular interaction"><entity charOffset="81-94" id="DDI-PubMed.31678378.s2.e0" text="teriflunomide" /><entity charOffset="96-99" id="DDI-PubMed.31678378.s2.e1" text="TEF" /><entity charOffset="105-115" id="DDI-PubMed.31678378.s2.e2" text="ketoprofen" /><entity charOffset="117-120" id="DDI-PubMed.31678378.s2.e3" text="KTP" /><entity charOffset="201-206" id="DDI-PubMed.31678378.s2.e4" text="Azone" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e0" e2="DDI-PubMed.31678378.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e0" e2="DDI-PubMed.31678378.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e0" e2="DDI-PubMed.31678378.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e0" e2="DDI-PubMed.31678378.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e0" e2="DDI-PubMed.31678378.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e1" e2="DDI-PubMed.31678378.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e1" e2="DDI-PubMed.31678378.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e1" e2="DDI-PubMed.31678378.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e1" e2="DDI-PubMed.31678378.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e2" e2="DDI-PubMed.31678378.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e2" e2="DDI-PubMed.31678378.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e2" e2="DDI-PubMed.31678378.s2.e4" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e3" e2="DDI-PubMed.31678378.s2.e3" /><pair ddi="false" e1="DDI-PubMed.31678378.s2.e3" e2="DDI-PubMed.31678378.s2.e4" /></sentence><sentence text=" The formulation was optimized using in vitro skin permeation study and confirmed with pharmacodynamics study, anti-inflammatory study and analgesics study" /><sentence text=" Enhanced drug-drug interaction by AZ was characterized using FT-IR, 13C NMR, molecular modeling and thermal analysis" /><sentence text=" The optimized formulation was composed of TEF (3%), KTP (2%), AZ (10%) and DURO-TAK® 87-4098 as adhesive matrix"><entity charOffset="43-46" id="DDI-PubMed.31678378.s5.e0" text="TEF" /><entity charOffset="53-56" id="DDI-PubMed.31678378.s5.e1" text="KTP" /><entity charOffset="76-84" id="DDI-PubMed.31678378.s5.e2" text="DURO-TAK" /><pair ddi="false" e1="DDI-PubMed.31678378.s5.e0" e2="DDI-PubMed.31678378.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s5.e0" e2="DDI-PubMed.31678378.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31678378.s5.e0" e2="DDI-PubMed.31678378.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31678378.s5.e1" e2="DDI-PubMed.31678378.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31678378.s5.e1" e2="DDI-PubMed.31678378.s5.e2" /></sentence><sentence text=" The skin permeation amount of TEF-KTP combination was promoted by AZ about 1"><entity charOffset="31-38" id="DDI-PubMed.31678378.s6.e0" text="TEF" /><entity charOffset="35-42" id="DDI-PubMed.31678378.s6.e1" text="KTP" /><pair ddi="false" e1="DDI-PubMed.31678378.s6.e0" e2="DDI-PubMed.31678378.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s6.e0" e2="DDI-PubMed.31678378.s6.e1" /></sentence><sentence text="9 times (594" /><sentence text="2 ± 46" /><sentence text="8 μg/cm2) and 1" /><sentence text="2 times (502" /><sentence text="92 ± 24" /><sentence text="0 μg/cm2) compared with TEF-AZ and KTP-AZ individual patch"><entity charOffset="24-26" id="DDI-PubMed.31678378.s12.e0" text="TEF" /><entity charOffset="35-37" id="DDI-PubMed.31678378.s12.e1" text="KTP" /><pair ddi="false" e1="DDI-PubMed.31678378.s12.e0" e2="DDI-PubMed.31678378.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s12.e0" e2="DDI-PubMed.31678378.s12.e1" /></sentence><sentence text=" It was proved that the interaction between TEF and KTP via hydrogen bonding was further enhanced by AZ due to the increased molecular mobility of acrylate polymer (ΔTg = -17"><entity charOffset="60-68" id="DDI-PubMed.31678378.s13.e0" text="hydrogen" /><entity charOffset="147-155" id="DDI-PubMed.31678378.s13.e1" text="acrylate" /><entity charOffset="44-51" id="DDI-PubMed.31678378.s13.e2" text="TEF" /><entity charOffset="52-59" id="DDI-PubMed.31678378.s13.e3" text="KTP" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e2" e2="DDI-PubMed.31678378.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e2" e2="DDI-PubMed.31678378.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e2" e2="DDI-PubMed.31678378.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e2" e2="DDI-PubMed.31678378.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e3" e2="DDI-PubMed.31678378.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e3" e2="DDI-PubMed.31678378.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e3" e2="DDI-PubMed.31678378.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e0" e2="DDI-PubMed.31678378.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31678378.s13.e0" e2="DDI-PubMed.31678378.s13.e1" /></sentence><sentence text="7 °C), which was proved by FTIR and 13C NMR spectra" /><sentence text=" The enhanced drug-drug intermolecular interaction increased drug dispersed status and decreased the quantity of drug's hydrogen bonding site, thus increasing the drug release amount significantly"><entity charOffset="120-128" id="DDI-PubMed.31678378.s15.e0" text="hydrogen" /></sentence><sentence text=" In conclusion, a compound transdermal patch containing KTP and TEF was developed successfully and a novel enhancement mechanism was clarified at molecular level, which provided reference for the development of novel compound transdermal patch"><entity charOffset="64-71" id="DDI-PubMed.31678378.s16.e0" text="TEF" /><entity charOffset="56-63" id="DDI-PubMed.31678378.s16.e1" text="KTP" /><pair ddi="false" e1="DDI-PubMed.31678378.s16.e1" e2="DDI-PubMed.31678378.s16.e1" /><pair ddi="false" e1="DDI-PubMed.31678378.s16.e1" e2="DDI-PubMed.31678378.s16.e0" /></sentence><sentence text="" /></document>